Multiple Sclerosis Drugs - Bangladesh

The Multiple Sclerosis Drugs market in Bangladesh is forecasted to achieve a revenue of US$14.00m in 2024.
This market is expected to experience a yearly growth rate of 2.72% (CAGR 2024-2029), leading to a market volume of US$16.01m by 2029.
When compared globally, United States is projected to generate the highest revenue of US$11.77bn in 2024.
Bangladesh's market for Multiple Sclerosis drugs is witnessing a growing demand for affordable treatment options to cater to the increasing number of patients.

Definition:
This market covers drugs to treat the neurological autoimmune disease multiple sclerosis. As there is no cure for multiple sclerosis, the goal is to improve functions after an attack or to prevent attacks. Different types of medication include immunomodulators, immunosuppressants, and interferons. Monoclonal antibodies are now being increasingly used.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: Biogen, Roche, Novartis, Sanofi

Drugs to treat multiple sclerosis
Monoclonal antibodies
Immunosuppressants

Monoclonal antibodies and immunosuppressants for the treatment of other diseases
Treatment of other autoimmune diseases
Alternative medicine

The Multiple Sclerosis Drugs market in Bangladesh is showing positive growth in recent years.

Customer preferences: Patients suffering from Multiple Sclerosis in Bangladesh are opting for advanced and effective treatment options. They prefer drugs that are affordable and can help them manage their symptoms effectively.

Trends in the market: The Multiple Sclerosis Drugs market in Bangladesh is witnessing a surge in demand due to the increasing prevalence of the disease. The market is dominated by branded drugs, but there is a growing trend towards the use of generic drugs. The market is also witnessing an increase in the number of clinical trials for new drugs.

Local special circumstances: Bangladesh has a large population, and the prevalence of Multiple Sclerosis is increasing due to changing lifestyles and environmental factors. There is a lack of awareness about the disease, and patients often do not have access to proper healthcare facilities. The government is taking initiatives to improve healthcare infrastructure and provide better access to treatment for patients.

Underlying macroeconomic factors: Bangladesh is a developing country with a growing economy. The pharmaceutical industry is one of the fastest-growing sectors in the country. The government is providing incentives to attract foreign investment in the pharmaceutical industry. The increasing prevalence of Multiple Sclerosis and the growing demand for effective treatment options are driving the growth of the Multiple Sclerosis Drugs market in Bangladesh.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

The pharmaceutical industry is responsible for the research, development, production, and distribution of medications. The market has experienced significant growth during the past two decades, and pharma revenues worldwide totaled 1.48 trillion U.S. dollars in 2022.